Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.65 and traded as high as $0.75. Lexicon Pharmaceuticals shares last traded at $0.73, with a volume of 2,479,330 shares traded.
Wall Street Analysts Forecast Growth
LXRX has been the topic of several research reports. Leerink Partnrs downgraded shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and set a $4.00 price target on shares of Lexicon Pharmaceuticals in a research report on Tuesday. Piper Sandler reduced their price target on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Finally, Leerink Partners reiterated a "market perform" rating and set a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $3.67.
Get Our Latest Analysis on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Trading Up 3.4%
The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.22. The company has a market capitalization of $335.93 million, a price-to-earnings ratio of -1.82 and a beta of 1.00. The business's 50-day simple moving average is $0.68 and its 200-day simple moving average is $0.65.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 568.04% and a negative return on equity of 103.16%. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.26 million. On average, research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its position in shares of Lexicon Pharmaceuticals by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock valued at $552,000 after acquiring an additional 15,249 shares during the period. Arizona State Retirement System raised its position in shares of Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 16,136 shares during the period. Teacher Retirement System of Texas raised its position in shares of Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock valued at $48,000 after acquiring an additional 24,615 shares during the period. Bank of America Corp DE raised its position in shares of Lexicon Pharmaceuticals by 27.4% in the 4th quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company's stock valued at $101,000 after acquiring an additional 29,319 shares during the period. Finally, Invesco Ltd. raised its position in shares of Lexicon Pharmaceuticals by 60.6% in the 4th quarter. Invesco Ltd. now owns 104,494 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 39,420 shares during the period. 74.70% of the stock is currently owned by institutional investors and hedge funds.
Lexicon Pharmaceuticals Company Profile
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Featured Articles
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
